Yahia Gawad, MB. Ch.B., MD., MSc., Founder/CEO and Director
Yahia was a co-founder of Syn X (previously Skye Pharmatech) where he held the position of Vice-President, Medical Affairs and prior to that, he was Director of Clinical Research at Spectral Diagnostics Inc. For the last 18 years, he has been working extensively on cardiac diagnostic test products, which he took from concept and bench development to commercialization, through regulatory approval processes. Dr. Gawad is a Physician/Scientist with primary training in Cardiology, Biochemistry and Immunology.
James A. Essex, CA, MBA, CFO. James has been with CardioGenics since 1999. He founded Hunter & Associates Inc. in 1990, a private financial consulting firm. Previously, he was a co-owner, President and COO of Calais Investigations, Inc., a private company (from 1993 to 1998), a Vice President of Confederation Trust (1989) and a Vice President of Chemical Bank of Canada (now Chase Manhattan Bank of Canada) from 1977 through 1987.
Linda J. Sterling, F.Inst.L.C.O., Corporate Secretary/Director. Linda has been managing CardioGenics’ legal affairs since 2003. Linda has been in the legal community in the capacity as a Law Clerk with both Stikeman Elliott LLP and Davies Ward Phillips & Vineberg LLP since 1999. She developed expertise with both public and private company legal compliance and has been responsible for CardioGenics' compliance and maintenance of corporate governance since 2001. She is licensed as a Legal Executive (F.Inst.L.C.O.); with the Institute of Law Clerks of Ontario, of which she is a member. She has held the position of CEO and director of Sterling Studios since 1989.
Karim Murabet, BA, MBA, Director. Karim has extensive business experience in diverse fields. He began his career as a professional soccer player around the world and went on to work in the sporting goods industry as the owner of Lanzera Italia. His passion for sports also led him to be a football manager in various countries. As an investor, he is currently co-owner of Libyan Italian Real Estate Investment Co. and a consultant and advisor to Gruppo Bonifaci, one of Italy's largest real estate developers, based in Rome. Karim currently resides in the United Arab Emirates and is a Partner and Director responsible for business development and public relations in ICap Group FZC, a property development, architecture, hotel management and investment company registered in the United Arab Emirates. Karim is a graduate of College du leman in Versoix, Switzerland and received a BA in human behavior and later an MBA in business from U.S. International University-San Diego.
Neil Tabatznik, Acting Chairman. Neil has been with CardioGenics since 2003. He is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from 0 to 700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by Merck KGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.
Board of Advisors
Prof. Robert Roberts, MD
Chairman & CEO, Ottawa Heart Institute
Prof. William Kostuk, MD
Professor of Medicine, U. Western Ontario